INDOUS
Start SIP
Invest Now
Start SIP in INDOUS
Performance
- Low
- ₹118
- High
- ₹132
- 52 Week Low
- ₹105
- 52 Week High
- ₹235
- Open Price₹127
- Previous Close₹125
- Volume7,295
- 50 DMA₹123.21
- 100 DMA₹130.81
- 200 DMA₹148.29
Investment Returns
- Over 1 Month -1.76%
- Over 3 Month -10.68%
- Over 6 Month -31.48%
- Over 1 Year -46.6%
Smart Investing Starts Here Start SIP with Indo US Bio-Tech for Steady Growth!
Indo US Bio-Tech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 16.2
- PEG Ratio
- 1.2
- Market Cap Cr
- 241
- P/B Ratio
- 2.8
- Average True Range
- 8.39
- EPS
- 7.4
- Dividend Yield
- 0
- MACD Signal
- -1.02
- RSI
- 49.17
- MFI
- 29.85
Indo US Bio-Tech Financials
Indo US Bio-Tech Technicals
EMA & SMA
Current Price
₹120.05
-6.05
(-4.8%)
- Bearish Moving Average 0
- Bullish Moving Average 0
- 20 Day
- ₹120.57
- 50 Day
- ₹123.21
- 100 Day
- ₹130.81
- 200 Day
- ₹148.29
Resistance and Support
124.47
- R3 142.13
- R2 137.72
- R1 128.88
- S1 115.63
- S2 111.22
- S3 102.38
Indo US Bio-Tech Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-01-21 | Quarterly Results | |
| 2025-11-14 | Quarterly Results | |
| 2025-10-14 | Others | Inter-alia, to consider 1. Re-appointment of M/s. Gautam N Associates as a Statutory Auditors of the Company. 2. Approve Notice of Postal Ballot. 3. Other business matters. per share(2.5%)Interim Dividend |
| 2025-08-12 | Quarterly Results | |
| 2025-05-26 | Audited Results |
Indo US Bio-Tech F&O
About Indo US Bio-Tech
- NSE Symbol
- INDOUS
- BSE Symbol
- 541304
- Managing Director
- Mr. Jagdish Ajudia
- ISIN
- INE250Z01010
Similar Stocks to Indo US Bio-Tech
Indo US Bio-Tech FAQs
Indo US Bio-Tech share price is ₹120 As on 02 February, 2026 | 02:21
The Market Cap of Indo US Bio-Tech is ₹240.7 Cr As on 02 February, 2026 | 02:21
The P/E ratio of Indo US Bio-Tech is 16.2 As on 02 February, 2026 | 02:21
The PB ratio of Indo US Bio-Tech is 2.8 As on 02 February, 2026 | 02:21
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.